IMMU-103
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 49 | 全身性エリテマトーデス | 9 |
49. 全身性エリテマトーデス
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
Showing 1 to 9 of 9 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-000705-59-DE (EUCTR) | 11/04/200620060411 | 07/06/200520050607 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems - Phase III Study of Epratuzumab in Severe Acute SLE Flares A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzuma ... | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems - Phase III Study of Epratuzumab in Severe Acute SLE Flares A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzuma ... | Systemic Lupus Erythematosus Classification code 10042945 | Product Name: Epratuzumab Product Code: IMMU-103 Other descriptive name: hLL2 (trivial name or chemical description) Product Name: Epratuzumab Product Code: IMMU-103 Other descriptive name: hLL2 (trivial name or chemica ... | UCB Pharma, Inc | NULL | Not Recruiting | Female: yes Male: yes | 510 | Phase 3 | Hungary;United Kingdom;Germany;Spain;Italy | ||
| 2 | EUCTR2005-000705-59-HU (EUCTR) | 09/01/200620060109 | 12/10/200520051012 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems. - Phase III Study of Epratuzumab in Severe Acute SLE Flares A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzuma ... | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems. - Phase III Study of Epratuzumab in Severe Acute SLE Flares A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzuma ... | Systemic Lupus Erythematosus Classification code 10042945 | Product Name: Epratuzumab Product Code: IMMU-103 Other descriptive name: hLL2 (trivial name or chemical description) Product Name: Epratuzumab Product Code: IMMU-103 Other descriptive name: hLL2 (trivial name or chemica ... | Immunomedics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 510 | Phase 3 | Hungary;Slovakia;Spain;Germany;Italy;United Kingdom | ||
| 3 | EUCTR2005-000706-31-DE (EUCTR) | 05/01/200620060105 | 28/06/200520050628 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLE A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patie ... | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLE A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patie ... | Systemic Lupus Erythematosus Classification code 10042945 | Product Name: Epratuzumab Product Code: IMMU-103 Other descriptive name: hLL2 (trivial name or chemical description) Product Name: Epratuzumab Product Code: IMMU-103 Other descriptive name: hLL2 (trivial name or chemica ... | UCB Pharma Inc. | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | United Kingdom;Germany;Spain;Italy | ||
| 4 | EUCTR2005-000705-59-SK (EUCTR) | 14/10/200520051014 | 29/07/200520050729 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems. - Phase III Study of Epratuzumab in Severe Acute SLE Flares A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzuma ... | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems. - Phase III Study of Epratuzumab in Severe Acute SLE Flares A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzuma ... | Systemic Lupus Erythematosus Classification code 10042945 | Product Name: Epratuzumab Product Code: IMMU-103 Other descriptive name: hLL2 (trivial name or chemical description) Product Name: Epratuzumab Product Code: IMMU-103 Other descriptive name: hLL2 (trivial name or chemica ... | Immunomedics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 510 | Phase 3 | Hungary;Slovakia;Spain;Germany;Italy;United Kingdom | ||
| 5 | EUCTR2005-000706-31-IT (EUCTR) | 15/09/200520050915 | 30/09/200520050930 | A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients with Active Systemic LupusErythematosus A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Pati ... | A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients with Active Systemic LupusErythematosus A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Pati ... | improvement of signs and symptoms of Active Systemic Lupus Erythematosus MedDRA version: 8.1;Level: LLT;Classification code 10042945;Term: Systemic lupus erythematosus improvement of signs and symptoms of Active Systemic Lupus Erythematosus MedDRA version: 8.1;Level: ... | Product Name: Epatuzumab Product Code: hLL2,IMMU-103 | IMMUNOMEDICS | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | Germany;United Kingdom;Spain;Italy | |||
| 6 | EUCTR2005-000706-31-ES (EUCTR) | 25/07/200520050725 | 23/05/200620060523 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLE A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patie ... | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLE A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patie ... | Systemic Lupus Erythematosus Classification code 10042945 | Product Name: Epratuzumab Product Code: IMMU-103 INN or Proposed INN: Epratuzumab Other descriptive name: hLL2 (trivial name or chemical description) Product Name: Epratuzumab Product Code: IMMU-103 INN or Proposed INN: Epratuzumab Other descriptive nam ... | Immunomedics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | Belgium;Spain;Germany;Italy;United Kingdom | ||
| 7 | EUCTR2005-000706-31-BE (EUCTR) | 29/06/200520050629 | 26/07/200520050726 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLE A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patie ... | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLE A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patie ... | Systemic Lupus Erythematosus Classification code 10042945 | Product Name: Epratuzumab Product Code: IMMU-103 Other descriptive name: hLL2 (trivial name or chemical description) Product Name: Epratuzumab Product Code: IMMU-103 Other descriptive name: hLL2 (trivial name or chemica ... | UCB Pharma Inc. | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | Spain;Belgium;Germany;Italy;United Kingdom | ||
| 8 | EUCTR2005-000705-59-GB (EUCTR) | 07/06/200520050607 | 19/04/200520050419 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems - Phase III Study of Epratuzumab in Severe Acute SLE Flares A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzuma ... | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems - Phase III Study of Epratuzumab in Severe Acute SLE Flares A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzuma ... | Systemic Lupus Erythematosus Classification code 10042945 | Product Name: Epratuzumab Product Code: IMMU-103 Other descriptive name: hLL2 (trivial name or chemical description) Product Name: Epratuzumab Product Code: IMMU-103 Other descriptive name: hLL2 (trivial name or chemica ... | Immunomedics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 510 | Phase 3 | Hungary;Germany;United Kingdom;Spain;Italy | ||
| 9 | EUCTR2005-000706-31-GB (EUCTR) | 13/05/200520050513 | 19/04/200520050419 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLE A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patie ... | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLE A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patie ... | Systemic Lupus Erythematosus Classification code 10042945 | Product Name: Epratuzumab Product Code: IMMU-103 Other descriptive name: hLL2 (trivial name or chemical description) Product Name: Epratuzumab Product Code: IMMU-103 Other descriptive name: hLL2 (trivial name or chemica ... | Immunomedics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | Germany;United Kingdom;Spain;Italy |